News Release(2023)
2023
-
December 12, 2023
KORSUVA® IV Injection Syringe for Dialysis 17.5μg, 25.0μg and 35.0μg to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis
-
December 1, 2023
Notice Concerning Status of Acquisition of the Company's Own Shares
-
November 17, 2023
Kissei Introduces Natural Language Processing System
-
November 7, 2023
Announcement concerning the Results of the Acquisition of Treasury Shares through ToSTNeT-3
-
November 6, 2023
Notice concerning the Purchase of Treasury Shares through ToSTNeT-3
-
November 1, 2023
Notice Concerning Status of Acquisition of the Company's Own Shares
-
October 27, 2023
Notice Concerning Revisions to Financial Results Forecast
-
October 23, 2023
Results of Japanese Phase III Clinical Study of KORSUVA® IV Injection for Pruritus in Patients undergoing Hemodialysis Published in NEJM Evidence
-
October 2, 2023
Notice Concerning Status of Acquisition of the Company's Own Shares
-
September 25, 2023
KORSUVA® IV Injection Syringe 17.5μg, 25.0μg and 35.0μg Granted Marketing Authorization Approval in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis
-
September 1, 2023
Notice Concerning Status of Acquisition of the Company's Own Shares
-
August 1, 2023
Notice Concerning Status of Acquisition of the Company's Own Shares
-
July 19, 2023
KISSEI Announces Withdrawal of Application for Marketing Approval for Rovatirelin (KPS-0373) for the Treatment of Spinocerebellar Degeneration in Japan
-
July 3, 2023
Kissei Introduces Iktos AI Drug Discovery System
-
July 3, 2023
Notice Concerning Status of Acquisition of the Company's Own Shares
-
June 1, 2023
Notice Concerning Status of Acquisition of the Company's Own Shares
-
May 8, 2023
Notice Regarding Purchase of Treasury Shares and Cancellation of Treasury Shares
-
April 21, 2023
Notice Concerning Revisions to Financial Results Forecast
-
April 6, 2023
Kissei Launches TAVALISSE® Tab. 100mg and 150mg, an Oral Spleen Tyrosine Kinase Inhibitor, in Japan for Chronic ITP